+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders



The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders



British Journal of Haematology 136(5): 745-751



The JAK2 V617F mutation is a frequent genetic event in the three classical Philadelphia-chromosome negative chronic myeloproliferative disorders (Ph(neg.)-CMPD), polycythemia vera (PV), essential thrombocythemia (ET) and idiopathic myelofibrosis (IMF). Its occurrence varies in frequency in regards to phenotype. The mutation is found in the majority of patients with PV and about half of the patients with ET and IMF. These diseases are clonal stem cell disorders arising in an early stem cell progenitor. The level in the stem cell hierarchy on which the initiating genetic events and the JAK2 V617F mutation occurs is not known. The mutation has so far been detected in all cells of the myeloid lineage, whereas the potential clonal involvement of the lymphoid lineage is controversial. In this study, we detected the JAK2 V617F mutation by real-time quantitative PCR (qPCR) in both B-lymphocytes and T-lymphocytes in a subgroup of patients with Ph(neg.)-CMPDs. These results demonstrate the origin of the JAK2 V617F positive disorders in an early stem cell with both lymphoid and myeloid differentiation potential.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 013021845

Download citation: RISBibTeXText

PMID: 17313377

DOI: 10.1111/j.1365-2141.2007.06497.x


Related references

Evaluation of V617F mutation of JAK2 in negative chromosome Philadelphia chronic myeloproliferative disorders. Medicina Clinica 127(16): 601-604, 2006

The JAK2 V617F mutation in Philadelphia-negative chronic myeloproliferative disorders (vol 60, pg 1070, 2007). 2007

JAK2 V617F mutation in leukaemic transformation of philadelphia-negative chronic myeloproliferative disorders. British Journal of Haematology 135(2): 267-268, 2006

The JAK2 V617F mutation is frequently present in buccal swabs from patients suffering from Philadelphia-negative chronic myeloproliferative disorders, who carry the mutation detected in bone marrow or peripheral blood cells [corrected. Journal of Clinical Pathology 60(9): 1070-1071, 2007

The first international meeting on V617F JAK2 mutation and its relevance in Philadelphia-negative myeloproliferative disorders. Pathologie-Biologie 55(2): 85-87, 2007

JAK2 V617F detected in two B-cell chronic lymphocytic leukemia patients without coexisting Philadelphia chromosome-negative myeloproliferative neoplasms: A report of two cases. Oncology Letters 8(2): 841-844, 2014

Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood 110(1): 375-379, 2007

Real-Time PCR and Droplet Digital PCR: two techniques for detection of the JAK2(V617F) mutation in Philadelphia-negative chronic myeloproliferative neoplasms. International Journal of Laboratory Hematology 37(6): 766-773, 2015

The incidence of JAK2 V617F mutation in bcr/abl-negative chronic myeloproliferative disorders: assessment by two different detection methods. Leukemia and Lymphoma 49(10): 1907-1915, 2008

The impact of JAK2 non-receptor tyrosine kinase mutation on the mobilization of hematopoietic stem cells into peripheral blood of patients with Philadelphia chromosome-negative myeloproliferative disorders. International Journal of Cancer 125(4): 988-990, 2009

The allele burden of JAK2 V617F can aid in differential diagnosis of Philadelphia Chromosome-Negative Myeloproliferative Neoplasm. Blood Research 48(2): 128-132, 2013

A case of polycythemia rubra vera transforming into chronic phase JAK2 V617F mutation-negative Philadelphia chromosome-positive chronic myelogenous leukemia. Leukemia and Lymphoma 54(7): 1567-1568, 2013

Prevalence of JAK2 V617F mutation in Indian patients with chronic myeloproliferative disorders. Indian Journal of Medical Research 132: 423-427, 2010

Incidence and significance of the JAK2 V617F mutation in patients with chronic myeloproliferative disorders. Irish Journal of Medical Science 176(2): 105-109, 2007